Oxybutynin Transdermal
Links shared publicly online about this topic
Transdermal oxybutynin may improve work productivity | News | Nursing Times
nursingtimes.net — “A study on Transdermal oxybutynin has found that it may improve work productivity” View full resource at nursingtimes.net
Most Recently Shared on August 3, 2009 at 3:57 pm By:
News: Transdermal oxybutynin may improve work productivity http://bit.ly/1398QK
Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment Of Overactive Bladder
medicalnewstoday.com — “Antares Pharma, Inc. (NYSE Amex: AIS) announced that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin A” View full resource at medicalnewstoday.com
Most Recently Shared on March 4, 2010 at 4:12 pm By:
MNT Clinical Trials Health News
Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment... http://mnt.to/3ysd
Phase 3 study of Anturol for the treatment of overactive bladder (OAB) - MPR
empr.com — “Antares Pharma announced that it has completed enrollment in the double-blind portion of their Phase 3 trial of Anturol (transdermal oxybutynin ATD gel) for the treatment of overactive bladder (OAB).” View full resource at empr.com
Most Recently Shared on March 2, 2010 at 4:03 pm By:
MPR News: Phase 3 study of Anturol for the treatment of overactive bladder (OAB): Antares Pharma announced that it... http://bit.ly/bmHRqt
Phase 3 study of Anturol for the treatment of overactive bladder (OAB) - ONA
oncologynurseadvisor.com — “Antares Pharma announced that it has completed enrollment in the double-blind portion of their Phase 3 trial of Anturol (transdermal oxybutynin ATD gel) for the treatment of overactive bladder (OAB).” View full resource at oncologynurseadvisor.com
Most Recently Shared on March 2, 2010 at 3:58 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Phase 3 study of Anturol for the treatment of overactive bladder (OAB) http://goo.gl/fb/FPaY
Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB
news-medical.net — “Antares Pharma, Inc. announced today that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol", its transdermal oxybutynin ATD" gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA), is expected in the third quarter of this year.” View full resource at news-medical.net
Most Recently Shared on March 2, 2010 at 2:08 pm By:
Antares Pharma completes enrollment in Phase 3 clinical trial of Anturol for OAB: Antares Pharma, Inc. announced t... http://bit.ly/c5DxQc
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Nursing Times
All the news, practice and opinion from NursingTimes.net. Drop us an @ to say hi!
-
MNT Clinical Trials
The latest clinical trials news published daily. Articles from research centers, universities and prestigious journals.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
